Pfizer Ahead Of Guidance In India, President Of Established Products Business Unit David Simmons Tells PharmAsia News
David Simmons, President at Pfizer's Established Products Business Unit says he is very positive about his company's deals struck earlier this year with Aurobindo and Claris. The two Indian companies will help Pfizer bulk up more than 100 oral and injectable formulations and turn the business unit cash positive in the next two to three years. Pfizer will sell the loss-of-exclusivity products through its Greenstone arm in the United States will likely launch those in Europe, Japan and a host of emerging markets. PharmAsia News' India bureau sat down with Simmons to find out more about Pfizer's pipeline and plans in India.
Keep up with the top pharma business news of the week. On the go.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains